« Back to Medicines list

Gaviscon Liquid Aniseed Flavour

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 15/01/20

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 14/6/2016
print

Print ViewKeyword Search SPC

Reckitt Benckiser Ireland Limited

Reckitt Benckiser Ireland Limited

Company Products

Medicine NameActive Ingredients
Medicine Name Bonjela Oromucosal Gel Active Ingredients Cetalkonium Chloride, Choline Salicylate
Medicine Name Bonjela Teething Gel Oromucosal Gel Active Ingredients Cetalkonium Chloride, Choline Salicylate
Medicine Name Dettol Antiseptic Disinfectant 4.8 % w/v Concentrate for Cutaneous Solution Active Ingredients Chloroxylenol
Medicine Name Disprin Direct 300mg Orodispersible Tablets Active Ingredients Aspirin
Medicine Name Disprin Extra Strength 500mg Effervescent Tablets Active Ingredients Acetylsalicylic Acid
Medicine Name Disprin Original 300mg Dispersible Tablets Active Ingredients Acetylsalicylic acid (Aspirin)
Medicine Name E45 Cream Active Ingredients Anhydrous Lanolin, Light Liquid Paraffin, White Soft Paraffin
Medicine Name Fybogel Citrus Active Ingredients Ispaghula Husk
Medicine Name Fybogel Mebeverine Active Ingredients Ispaghula Husk, Mebeverine Hydochloride
Medicine Name Fybogel Orange 3.5g Granules Active Ingredients Ispaghula Husk
Medicine Name Gaviscon Advance Chewable Tablets Active Ingredients Potassium Bicarbonate, Sodium Alginate
Medicine Name Gaviscon Advance Oral Suspension Active Ingredients Potassium hydrogen carbonate, Sodium Alginate
Medicine Name Gaviscon Extra Chewable Tablets Active Ingredients Calcium Carbonate, Sodium Alginate, Sodium Bicarbonate
Medicine Name Gaviscon Extra Liquid Sachets Peppermint Flavour Active Ingredients Calcium Carbonate, Sodium Alginate, Sodium Bicarbonate
Medicine Name Gaviscon Extra Oral Suspension Active Ingredients Calcium Carbonate, Sodium Alginate, Sodium Bicarbonate
Medicine Name Gaviscon Infant Active Ingredients Magnesium Alginate, Sodium Alginate
Medicine Name Gaviscon Liquid - Peppermint Flavour Active Ingredients Calcium Carbonate, Sodium Alginate, Sodium Bicarbonate
Medicine Name Gaviscon Liquid Aniseed Flavour Active Ingredients Calcium Carbonate, Sodium Alginate, Sodium Bicarbonate
Medicine Name Gaviscon Peppermint Chewable Tablets Active Ingredients Calcium Carbonate, Sodium Alginate, Sodium Hydrogen Carbonate
Medicine Name Gaviscon Suspension Active Ingredients Calcium Carbonate, Sodium Alginate, Sodium Bicarbonate
Medicine Name Hc45 Hydrocortisone Acetate 1% w/w Cream Active Ingredients Hydrocortisone Acetate
Medicine Name Lemsip Chesty Cough 50 mg/5 ml Oral Solution Active Ingredients Guaifenesin
Medicine Name Lemsip Cold & Flu Headcold 500mg Powder for Oral Solution Active Ingredients Paracetamol
Medicine Name Lemsip Cold & Flu Hot Lemon 500mg Powder for Oral Solution Active Ingredients Paracetamol
Medicine Name Lemsip Cold + Flu Headcold Active Ingredients Paracetamol
1 - 0 of 64 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 15 January 2020 PIL

Reasons for updating

  • New PIL for new product

Updated on 14 June 2016 SPC

Reasons for updating

  • New SPC for new product

Legal category: Supply through general sale

Updated on 14 June 2016 SPC

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration

Legal category: Supply through general sale

Free text change information supplied by the pharmaceutical company

100ml bottle size has been removed from Section 4.1 and section 4.2 of SmPC

Updated on 14 June 2016 PIL

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration

Free text change information supplied by the pharmaceutical company

100ml bottle size has been removed from Section 4.1 and section 4.2 of SmPC

Updated on 19 April 2016 SPC

Reasons for updating

  • Change to section 6.5 - Nature and contents of container

Legal category: Supply through general sale

Free text change information supplied by the pharmaceutical company

Section 6.5 - 100ml bottle size has been deleted

Updated on 19 April 2016 PIL

Reasons for updating

  • Change to section 6.5 - Nature and contents of container

Free text change information supplied by the pharmaceutical company

Section 6.5 - 100ml bottle size has been deleted

Updated on 8 September 2014 PIL

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

In section 4.2 - The format has changed. Additional information has been added regarding special patient groups. Added that the clinical situation should be reviewed after 7 days.

Section 4.4 - Added that if symptoms persist after 7 days to consult a doctor. Added additional warnings regarding excipients.

Section 4.5 - Added a time interval between taking Gaviscon and other products.

Section 4.6 - Added specific information to each category Pregnancy, Breast-feeding, and Fertility

Section 4.7 - Changed wording.

Section 4.8 - The format has changed. Added information on how to report suspected adverse events.

Section 10 - Updated the date of revision of the text.

Updated on 8 September 2014 SPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Supply through general sale

Free text change information supplied by the pharmaceutical company

In section 4.2 - The format has changed. Additional information has been added regarding special patient groups. Added that the clinical situation should be reviewed after 7 days.

Section 4.4 - Added that if symptoms persist after 7 days to consult a doctor. Added additional warnings regarding excipients.

Section 4.5 - Added a time interval between taking Gaviscon and other products.

Section 4.6 - Added specific information to each category Pregnancy, Breast-feeding, and Fertility

Section 4.7 - Changed wording.

Section 4.8 - The format has changed. Added information on how to report suspected adverse events.

Section 10 - Updated the date of revision of the text.

Updated on 13 December 2012 PIL

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use

Free text change information supplied by the pharmaceutical company

In section 4.4, added "Contains methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) which may cause allergic reactions (possibly delayed)".

Updated on 13 December 2012 SPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use

Legal category: Supply through general sale

Free text change information supplied by the pharmaceutical company

In section 4.4, added "Contains methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) which may cause allergic reactions (possibly delayed)".

Updated on 15 May 2007 PIL

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.3 - Contraindications
  • Change to section 4.8 - Undesirable effects

Free text change information supplied by the pharmaceutical company

SECTION 2.  Qualitative and Quantitative Composition expanded to include the concentration of sodium and parahydroxybenzoate per 10ml dose
 
SECTION 4.3.  Contraindications now includes a statement on hypersensitivity to any of the ingredients.
 
SECTION 4.8.  Allergic manifestations expanded to include anaphylactic and anaphylactoid reactions
 
SECTION 7.  Change of address of marketing authorisation holder to: 7 Riverwalk, Citywest Business Campus, Dublin 24, Ireland.

Updated on 15 May 2007 SPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.3 - Contraindications
  • Change to section 4.8 - Undesirable effects

Legal category: Supply through general sale

Free text change information supplied by the pharmaceutical company

SECTION 2.  Qualitative and Quantitative Composition expanded to include the concentration of sodium and parahydroxybenzoate per 10ml dose
 
SECTION 4.3.  Contraindications now includes a statement on hypersensitivity to any of the ingredients.
 
SECTION 4.8.  Allergic manifestations expanded to include anaphylactic and anaphylactoid reactions
 
SECTION 7.  Change of address of marketing authorisation holder to: 7 Riverwalk, Citywest Business Campus, Dublin 24, Ireland.

Updated on 9 August 2006 PIL

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 6.3 - Shelf life
  • Change to section 6.5 - Nature and contents of container

Free text change information supplied by the pharmaceutical company

Changes to pack sizes in sections 4.1, 4.2, 4.4 and 6.5.  Pack sizes of 200 and 300ml have been removed from the sections denoting packs for retail sale through pharmacies only and a 300 ml pack has been added to the sections denoting packs for general sale.

Reduction in shelf-life from three years to two years in section 6.3

Updated on 9 August 2006 SPC

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 6.3 - Shelf life
  • Change to section 6.5 - Nature and contents of container

Legal category: Supply through general sale

Free text change information supplied by the pharmaceutical company

Changes to pack sizes in sections 4.1, 4.2, 4.4 and 6.5.  Pack sizes of 200 and 300ml have been removed from the sections denoting packs for retail sale through pharmacies only and a 300 ml pack has been added to the sections denoting packs for general sale.

Reduction in shelf-life from three years to two years in section 6.3

Updated on 19 May 2005 PIL

Reasons for updating

  • Improved electronic presentation

Updated on 19 May 2005 SPC

Reasons for updating

  • Improved electronic presentation

Legal category: Supply through general sale

Updated on 10 August 2004 SPC

Reasons for updating

  • Improved electronic presentation

Legal category: Supply through general sale

Updated on 10 August 2004 PIL

Reasons for updating

  • Improved electronic presentation

Updated on 20 August 2003 PIL

Reasons for updating

  • Change to section 9 - Date of renewal of authorisation

Updated on 20 August 2003 SPC

Reasons for updating

  • Change to section 9 - Date of renewal of authorisation

Legal category: Supply through general sale

Updated on 16 June 2003 SPC

Reasons for updating

  • New SPC for medicines.ie

Legal category: Supply through general sale

Updated on 16 June 2003 PIL

Reasons for updating

  • New SPC for medicines.ie